Pediatric community-acquired pneumonia treated with a three-day course of tebipenem pivoxil

The World's First Oral Carbapenem Study Group

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


We evaluated the efficacy and safety of a 3-day treatment regimen of tebipenem pivoxil for pediatric community-acquired pneumonia. Tebipenem pivoxil was administered to 49 patients, and its effectiveness was evaluated in 36 patients 2–4 days after initiation of treatment. Thirty-two patients were cured 7–15 days after initiation of treatment. Body temperature was significantly lower on the day following initial administration (median 38.8 to 37.0 °C, n = 33). Leukocyte counts and C-reactive protein levels were significantly reduced by Day 2–4 of treatment (median 16,100 to 7800 white blood cells/μL, and 5.6 to 1.5 mg/dL, respectively; n = 28). Six of the 49 patients had mild diarrhea. Thus, we concluded that 3-day treatment with tebipenem pivoxil was safe and efficacious for treating pediatric community-acquired pneumonia.

Original languageEnglish
Pages (from-to)307-311
Number of pages5
JournalJournal of Infection and Chemotherapy
Issue number5
Publication statusPublished - 2017 May 1


  • Community-acquired pneumonia
  • Pediatric
  • Tebipenem pivoxil

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Pediatric community-acquired pneumonia treated with a three-day course of tebipenem pivoxil'. Together they form a unique fingerprint.

Cite this